Joinn Laboratories China Ltd. logo

Joinn Laboratories China Ltd. (6127)

Market Closed
17 Aug, 08:00
HKEX HKEX
26. 66
HKD
+1.58
+6.2998%
HKD
- Market Cap
- P/E Ratio
1% Div Yield
6.08M Volume
- Eps
25.08 HKD
Previous Close
Add Transaction
Day Range
24.66 27.02
Year Range
15.13 29.98
Want to track 6127 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

6127 closed today higher at 26.66 HKD, an increase of 6.2998% from yesterday's close, completing a monthly increase of 35.5363% or 6.99 HKD. Over the past 12 months, 6127 stock gained 29.4175%.
6127 pays dividends to its shareholders, with the most recent payment made on Aug 04, 2026. The next estimated payment will be in In 11 months on Aug 04, 2027 for a total of 0.13786 HKD.
The last earnings report, released on Mar 31, 2026, missed the consensus estimates by -0.336%. On average, the company has fell short of earnings expectations by -0.168%, based on the last three reports.
Joinn Laboratories China Ltd. has completed 3 stock splits, with the recent split occurring on Jun 20, 2023.
The company's stock is traded on one exchange.

6127 Chart

Joinn Laboratories China Ltd. (6127) FAQ

What is the stock price today?

The current price is 26.66 HKD.

On which exchange is it traded?

Joinn Laboratories China Ltd. is listed on HKEX.

What is its stock symbol?

The ticker symbol is 6127.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1%.

What is its market cap?

As of today, no market cap data is available.

Has Joinn Laboratories China Ltd. ever had a stock split?

Joinn Laboratories China Ltd. had 3 splits and the recent split was on Jun 20, 2023.

Joinn Laboratories China Ltd. Profile

Professional Services Industry
Industrials Sector
Dr. Yuxia Feng M.D. CEO
HKEX Exchange
CNE100004BP3 ISIN
CN Country
2,510 Employees
22 Jun 2026 Last Dividend
20 Jun 2023 Last Split
- IPO Date

Overview

Joinn Laboratories(China)Co.,Ltd. is a prominent provider of preclinical and non-clinical services, catering to an international clientele that includes the United States and the People's Republic of China. Since its inception in 1995, the company has grown to operate through three main segments, which encompass Non-Clinical Studies Services, Clinical Trial and Related Services, and Sales of Research Models. With its headquarters in Beijing, China, Joinn Laboratories is dedicated to supporting the development of new drugs by offering comprehensive services ranging from drug safety assessment to the sales of research models. Through its vast range of services, Joinn Laboratories plays a crucial role in the drug development process, catering to pharmaceutical and biotechnology companies globally.

Products and Services

  • Non-Clinical Studies Services: This segment is devoted to aiding drug development efforts through a variety of critical studies. It includes drug safety assessment, where the potential risks of new drugs are evaluated; drug metabolism and pharmacokinetics (DMPK) studies, which analyze how drugs are absorbed, distributed, metabolized, and excreted in the body; and pharmacology and efficacy studies, which assess the biological activity and efficacy of drug candidates.

  • Clinical Trial and Related Services: Joinn Laboratories offers comprehensive services that support clinical trials, including Contract Research Organization (CRO) services that cover a wide range of clinical trial needs. The company also has co-managed phase I clinical research units, which specialize in the initial phase of clinical trials to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug in humans. Additionally, bioanalytical services are provided to support the analysis of drugs and their metabolites in biological samples.

  • Sales of Research Models: This segment caters to the need for high-quality research models in the drug development process. Joinn Laboratories designs, produces, breeds, and sells a variety of research models, including non-human primates and rodents. These models are crucial for preclinical testing and other research applications, providing valuable insights into drug safety and efficacy before human trials commence.

  • Cell-Based Assay (CBA) Services: The company also specializes in cell-based assay services, which are vital for evaluating the cellular response to drugs. These assays are an essential tool in drug discovery and development, helping to elucidate mechanisms of action, verify drug efficacy, and screen for cytotoxicity.

Contact Information

Address: A5 Rongjing East Street, Beijing, China, 100176
Phone: 86 10 6786 9582